Strategic acquisition Helios Global Group was acquired by Telemos Capital in October 2024, signaling potential access to new capital, strategic support, and expanded resources to scale healthcare communications offerings.

Global footprint With headquarters in the UK and an established US base, Helios Global Group serves global, regional, and domestic clients, presenting opportunities to cross-sell across geographies and leverage multinational pharma relationships.

Full-service specialty Offering strategic consultancy, medical communications, commercialisation solutions and value evidence, the company can upsell integrated communications packages to pharma and biotech clients seeking end-to-end support.

Revenue range Current revenue is in the mid five-figure to low six-figure range per year, indicating room for growth through expanded client engagements, larger contracts, and expanded services with current or new customers.

Industry alignment Specialization in medical affairs, publications, market access and related communications positions the firm to pursue opportunities with drug launches, payer evidence needs, and policies driving access and reimbursement.